Modality
mRNA
MOA
JAK1/2i
Target
AHR
Pathway
Wnt
Crohn's
Development Pipeline
Preclinical
~Oct 2016
→ ~Jan 2018
Phase 1
Apr 2018
→ Dec 2026
Phase 1Current
NCT03027599
162 pts·Crohn's
2018-04→2026-12·Terminated
162 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-12-058mo awayInterim· Crohn's
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P1
Termina…
Catalysts
Interim
2026-12-05 · 8mo away
Crohn's
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03027599 | Phase 1 | Crohn's | Terminated | 162 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BAY-6520 | Bayer | Phase 2 | AHR | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Peminaritide | Sarepta | NDA/BLA | PLK4 | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR | |
| Niramavacamten | Hansoh Pharma | Phase 2 | SGLT2 |